ICD10monitor February 19, 2024
The Centers for Medicare & Medicaid Services (CMS) recently unveiled transcripts from a series of patient-focused listening sessions, a pivotal element of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.
These sessions, conducted between Oct. 30 and Nov. 15, 2023, marked a significant step forward in the Program’s mission to make prescription drugs more affordable for Medicare Part D enrollees. Specifically, these sessions focused on the inaugural set of 10 drugs selected for negotiation, which treat a range of medical conditions, including diabetes, blood clots, heart failure, psoriasis, rheumatoid arthritis, Crohn’s disease, and blood cancers.
The drugs in question – Farxiga, Fiasp/NovoLog, Januvia, Jardiance, Eliquis, Xarelto, Entresto, Stelara, Enbrel, and Imbruvica – were chosen for their clinical importance and...
Today's Sponsors
Today's Sponsor